Eukaryotic chromosomes have specialized structures at their termini called telomeres. Telomeres prevent natural chromosome ends from being recognized and processed as DNA double-strand breaks in need of repair ([@bib31]). Due to incomplete DNA replication and nucleolytic degradation, telomeres shorten with each round of cell division. Telomere shortening is reversed by the action of telomerase, a specialized reverse transcriptase that extends telomeres ([@bib21]). However, most human somatic cells do not express sufficient levels of telomerase to prevent telomere shortening, which has been implicated in human aging ([@bib38]). The downregulation of telomerase early during human development has been proposed to function as a barrier to tumorigenesis because cancers cells need to maintain their telomeres to avoid replicative senescence or apoptosis induced by telomere erosion ([@bib23]). Most cancer cells overcome this barrier by reactivating telomerase, but 10--15% of cancers employ a telomerase-independent pathway known as alternative lengthening of telomeres (ALT) ([@bib51]).

In the budding yeast *Saccharomyces cerevisiae*, telomerase is constitutively expressed, allowing the maintenance of telomeres 300 ± 75 bp in length ([@bib63]). The core components of telomerase in *S. cerevisiae* are a protein catalytic component ([Est2](http://www.yeastgenome.org/locus/S000004310/overview)) and an RNA subunit ([TLC1](http://www.yeastgenome.org/locus/S000006657/overview)) ([@bib37]; [@bib50]). Abrogating telomerase function, for example by deleting either *[EST2](http://www.yeastgenome.org/locus/S000004310/overview)* or *[TLC1](http://www.yeastgenome.org/locus/S000006657/overview)*, will cause telomere attrition and, eventually, cell cycle arrest and replicative senescence. A small subset of cells can overcome senescence and become what are called "survivors" ([@bib39]), using telomerase-independent telomere maintenance mechanisms as in ALT cancer cells.

There are two main types of *S. cerevisiae* survivors: type I and type II. Type I survivors exhibit amplification of the subtelomeric Y′ elements; in contrast, type II survivors amplify the terminal (TG~1-3~)~n~ telomeric sequences ([@bib39]; [@bib55]). Type I and type II survivors require Rad52-dependent homologous recombination (HR) and the DNA polymerase δ subunit [Pol32](http://www.yeastgenome.org/locus/S000003804/overview), which is required for break-induced replication (BIR), suggesting that both survivor pathways occur through recombination-dependent DNA replication ([@bib39]; [@bib40]). The [Pif1](http://www.yeastgenome.org/locus/S000004526/overview) helicase is also important for the generation of type I and type II survivors ([@bib15]), likely due to its role in BIR ([@bib47]; [@bib64]). There are two BIR pathways: one is [Rad51](http://www.yeastgenome.org/locus/S000000897/overview)-dependent and one is independent of [Rad51](http://www.yeastgenome.org/locus/S000000897/overview), but requires the MRX complex (consisting of [Mre11](http://www.yeastgenome.org/locus/S000004837/overview), [Rad50](http://www.yeastgenome.org/locus/S000005194/overview), and [Xrs2](http://www.yeastgenome.org/locus/S000002777/overview)) and [Rad59](http://www.yeastgenome.org/locus/S000002217/overview) ([@bib1]). Similarly, the formation of type I survivors is dependent on [Rad51](http://www.yeastgenome.org/locus/S000000897/overview) (and [Rad54](http://www.yeastgenome.org/locus/S000003131/overview) and [Rad57](http://www.yeastgenome.org/locus/S000002411/overview), which function in the same pathway as [Rad51](http://www.yeastgenome.org/locus/S000000897/overview)), whereas type II survivors require the MRX complex and [Rad59](http://www.yeastgenome.org/locus/S000002217/overview) ([@bib54]; [@bib10]), suggesting that type I and type II survivors maintain telomeres via [Rad51](http://www.yeastgenome.org/locus/S000000897/overview)-dependent and [Rad51](http://www.yeastgenome.org/locus/S000000897/overview)-independent BIR, respectively.

Type II survivors resemble the majority of human ALT cells in that both are characterized by long and heterogeneous-sized telomere length ([@bib55]; [@bib6]; [@bib5]), extrachromosomal circular DNA containing telomeric sequence ([@bib35]; [@bib7]; [@bib25]), and telomere maintenance by [Rad51](http://www.yeastgenome.org/locus/S000000897/overview)-independent BIR requiring the MRX (or MRN---Mre11, Rad50, Nbs1---in humans) complex ([@bib54]; [@bib10]; [@bib16]; [@bib33]; [@bib69]).

[Sgs1](http://www.yeastgenome.org/locus/S000004802/overview) and [Exo1](http://www.yeastgenome.org/locus/S000005559/overview), which are needed for processive resection of DNA ends ([@bib43]; [@bib70]), are also important for type II survivor formation ([@bib29]; [@bib34]; [@bib41]; [@bib4]). Consistent with the importance of end resection for type II survivor formation, the *[sgs1](http://www.yeastgenome.org/locus/S000004802/overview)-D664∆* mutation ([@bib3]; [@bib2]), which is competent for recombination repair but defective in resection, also prevents the formation of type II survivors ([@bib24]). Similarly, type II survivor formation is hindered by the deletion of *[FUN30](http://www.yeastgenome.org/locus/S000000017/overview)*, which encodes a chromatin remodeler that promotes end resection ([@bib13]). BLM, a human homolog of [Sgs1](http://www.yeastgenome.org/locus/S000004802/overview), has also been implicated in facilitating telomere maintenance in ALT cells ([@bib52]).

Several additional proteins have also been implicated in the formation of type II survivors. These include the [Tel1](http://www.yeastgenome.org/locus/S000000184/overview) and [Mec1](http://www.yeastgenome.org/locus/S000000340/overview) DNA damage checkpoint kinases: in the absence of either [Mec1](http://www.yeastgenome.org/locus/S000000340/overview) or [Tel1](http://www.yeastgenome.org/locus/S000000184/overview), type II survivor formation is impaired, and is completely abolished in *[mec1](http://www.yeastgenome.org/locus/S000000340/overview)Δ [tel1](http://www.yeastgenome.org/locus/S000000184/overview)Δ* double mutants ([@bib60]). Furthermore, the RNA polymerase II degradation factor [Def1](http://www.yeastgenome.org/locus/S000001537/overview), the B-type cyclin [Clb2](http://www.yeastgenome.org/locus/S000006323/overview), the tRNA modification protein [Sua5](http://www.yeastgenome.org/locus/S000003137/overview), and Mdt4/[Pin4](http://www.yeastgenome.org/locus/S000000147/overview), which interacts with the DNA damage kinase [Rad53](http://www.yeastgenome.org/locus/S000006074/overview), are also important for type II survivor formation ([@bib11]; [@bib20]; [@bib42]; [@bib46]). An analysis of 280 genes known to alter telomere length homeostasis when deleted further identified 22 genes that are important for type II survivor formation, including genes encoding members of the nonsense mediated decay pathway, the DNA repair protein [Rad6](http://www.yeastgenome.org/locus/S000003026/overview), and the KEOPS complex ([@bib27]). However, it is still unclear how most of these proteins function in the formation of type II survivors, and whether there are more proteins involved in this process.

In this study, we performed a genome-wide screen to identify novel genes that are important for the formation of type II survivors. We identified 23 genes, 17 of which were not previously reported to be involved in type II survivor formation. Several of these genes are involved in the regulation of intracellular deoxyribonucleoside triphosphate (dNTP) levels. We show that dNTP levels are increased early after inactivation of telomerase, and that this increase is important to generate type II survivors.

Materials and Methods {#s1}
=====================

Yeast strains and growth conditions {#s2}
-----------------------------------

Standard yeast media and growth conditions were used ([@bib58]; [@bib49]). With the exception of MCY610 and the yeast knockout (YKO) collection ([@bib19]), all yeast strains used in this study are *[RAD5](http://www.yeastgenome.org/locus/S000004022/overview)* derivatives of W303 ([@bib56]; [@bib67]) and are listed in [Table 1](#t1){ref-type="table"}. MCY610 has a hybrid BY4741 and W303 genetic background. Generation of survivors on agar plates and in liquid culture was performed as previously described ([@bib61]).

###### Yeast strains used in this study

  Strain name   Relevant genotype                                                                                                                                                           Source
  ------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------
  MCY610        *MAT***a**/α *can1∆STE2pr-HIS3/can1∆STE2pr-Sp_his5 lyp1∆/lyp1∆ rad51ΔURA3 /RAD51 est2∆natMX/EST2 TRP1/trp1-1 ADE2/ADE2 his3∆1/his3 leu2∆0/leu2 ura3∆0/ura3 RAD5/rad5-535*   This study
  CCY6          *MAT***a**/α *est2ΔURA3/EST2*                                                                                                                                               Clémence Claussin
  CCY16         *MAT***a**/α *est2ΔURA3/EST2 rad52ΔnatMX/RAD52*                                                                                                                             [@bib12]
  YPM7          *MAT***a**/α *est2ΔURA3/EST2 rad51ΔnatMX/RAD51 rad50ΔkanMX/RAD50*                                                                                                           This study
  YPM8          *MAT***a**/α *est2ΔURA3/EST2 rad51ΔnatMX/RAD51 rad59ΔkanMX/RAD59*                                                                                                           This study
  YPM9          *MAT***a**/α *est2ΔURA3/EST2 rad51ΔnatMX/RAD51*                                                                                                                             This study
  YPM10         *MAT***a**/α *est2ΔURA3/EST2 rad51ΔnatMX/RAD51 nmd2ΔkanMX/NMD2*                                                                                                             This study
  YPM11         *MAT***a**/α *est2ΔURA3/EST2 rad51ΔnatMX/RAD51 rgi1ΔkanMX/RGI1*                                                                                                             This study
  YPM12         *MAT***a**/α *est2ΔURA3/EST2 rad51ΔnatMX/RAD51 dun1ΔTRP1/DUN1 sml1ΔHIS3/SML1*                                                                                               This study
  YPM17         *MAT***a**/α *est2ΔURA3/EST2 rad51ΔnatMX/RAD51 clb2ΔkanMX/CLB2*                                                                                                             This study
  YPM20         *MAT***a**/α *est2ΔURA3/EST2 rad51ΔnatMX/RAD51 vps25ΔkanMX/VPS25*                                                                                                           This study
  YPM21         *MAT***a**/α *est2ΔURA3/EST2 rad51ΔnatMX/RAD51 lsm1ΔkanMX/LSM1*                                                                                                             This study
  YPM29         *MAT***a**/α *est2ΔURA3/EST2 rad51ΔnatMX/RAD51 rmi1ΔkanMX/RMI1*                                                                                                             This study
  YPM30         *MAT***a**/α *est2ΔURA3/EST2 rad51ΔnatMX/RAD51 spt20ΔkanMX/SPT20*                                                                                                           This study
  YPM31         *MAT***a**/α *est2ΔURA3/EST2 rad51ΔnatMX/RAD51 cdc55ΔkanMX/CDC55*                                                                                                           This study
  YPM32         *MAT***a**/α *est2ΔURA3/EST2 rad51ΔnatMX/RAD51 chk1ΔkanMX/CHK1*                                                                                                             This study
  YPM33         *MAT***a**/α *est2ΔURA3/EST2 rad51ΔnatMX/RAD51 pph3ΔkanMX/PPH3*                                                                                                             This study
  YPM34         *MAT***a**/α *est2ΔURA3/EST2 rad51ΔnatMX/RAD51 mot2ΔkanMX/MOT2*                                                                                                             This study
  YPM35         *MAT***a**/α *est2ΔURA3/EST2 rad51ΔnatMX/RAD51 rpn4ΔkanMX/RPN4*                                                                                                             This study
  YPM36         *MAT***a**/α *est2ΔURA3/EST2 rad51ΔnatMX/RAD51 ylr358cΔkanMX/YLR358C*                                                                                                       This study
  YPM37         *MAT***a**/α *est2ΔURA3/EST2 rad51ΔnatMX/RAD51 rrm3ΔkanMX/RRM3*                                                                                                             This study
  YPM38         *MAT***a**/α *est2ΔURA3/EST2 rad51ΔnatMX/RAD51 tsc3ΔkanMX/TSC3*                                                                                                             This study
  YPM39         *MAT***a**/α *est2ΔURA3/EST2 rad51ΔnatMX/RAD51 pxp1ΔkanMX/PXP1*                                                                                                             This study
  YPM40         *MAT***a**/α *est2ΔURA3/EST2 rad51ΔnatMX/RAD51 mtc7ΔkanMX/MTC7*                                                                                                             This study
  YPM41         *MAT***a**/α *est2ΔURA3/EST2 rad51ΔnatMX/RAD51 doa4ΔkanMX/DOA4*                                                                                                             This study
  YPM42         *MAT***a**/α *est2ΔURA3/EST2 rad51ΔnatMX/RAD51 cik1ΔkanMX/CIK1*                                                                                                             This study
  YPM43         *MAT***a**/α *est2ΔURA3/EST2 rad51ΔnatMX/RAD51 ure2ΔkanMX/URE2*                                                                                                             This study
  YPM44         *MAT***a**/α *est2ΔURA3/EST2 rad51ΔnatMX/RAD51 vma22ΔkanMX/VMA22*                                                                                                           This study
  YPM45         *MAT***a**/α *est2ΔURA3/EST2 rad51ΔnatMX/RAD51 rpl8bΔkanMX/RPL8B*                                                                                                           This study
  YPM48         *MAT***a**/α *est2ΔURA3/EST2 rad51ΔnatMX/RAD51 ylr235cΔkanMX/YLR235C*                                                                                                       This study
  YPM51         *MAT***a**/α *est2ΔURA3/EST2 rad51ΔnatMX/RAD51 ccr4ΔkanMX/CCR4*                                                                                                             This study
  YPM55         *MAT*α *est2ΔURA3* type II survivor                                                                                                                                         This study
  YPM56         *MAT*α *est2ΔURA3* type II survivor                                                                                                                                         This study
  MCY775        *MAT***a**/α *est2ΔURA3/EST2 dun1ΔTRP1/DUN1 sml1ΔHIS3/SML1*                                                                                                                 This study
  MCY783        *MAT***a** *est2ΔURA3* type II survivor                                                                                                                                     This study
  MCY784        *MAT***a** *est2ΔURA3* type II survivor                                                                                                                                     This study
  MCY785        *MAT***a** *est2ΔURA3 sml1∆HIS3* type II survivor                                                                                                                           This study
  MCY786        *MAT***a** *est2ΔURA3 sml1∆HIS3* type II survivor                                                                                                                           This study
  MCY788        *MAT***a** *est2ΔURA3 dun1∆TRP1 sml1∆HIS3* type II survivor                                                                                                                 This study
  YPM60         *MAT***a** *est2ΔURA3* type II survivor                                                                                                                                     This study
  YPM61         *MAT***a** *est2ΔURA3 dun1∆TRP1* type II survivor                                                                                                                           This study
  YPM62         *MAT***a** *est2ΔURA3 dun1∆TRP1* type II survivor                                                                                                                           This study
  YPM63         *MAT***a** *est2ΔURA3 dun1∆TRP1* type II survivor                                                                                                                           This study
  YPM64         *MAT***a** *est2ΔURA3 dun1∆TRP1 sml1∆HIS3* type II survivor                                                                                                                 This study
  YPM65         *MAT***a** *est2ΔURA3 dun1∆TRP1 sml1∆HIS3* type II survivor                                                                                                                 This study

SGA screening procedure {#s3}
-----------------------

The *[est2](http://www.yeastgenome.org/locus/S000004310/overview)∆* and *[rad51](http://www.yeastgenome.org/locus/S000000897/overview)∆* deletions were introduced into the strains of the YKO collection using synthetic genetic array (SGA) methodology ([@bib57]). The *MAT*α *[can1](http://www.yeastgenome.org/locus/S000000789/overview)∆[STE2](https://www.yeastgenome.org/locus/S000001868)pr-Sp\_[his5](https://www.yeastgenome.org/locus/S000001378)[est2](http://www.yeastgenome.org/locus/S000004310/overview)∆natMX [his3](http://www.yeastgenome.org/locus/S000005728/overview)[leu2](http://www.yeastgenome.org/locus/S000000523/overview)[lyp1](http://www.yeastgenome.org/locus/S000005212/overview)∆ [RAD5](http://www.yeastgenome.org/locus/S000004022/overview)[rad51](http://www.yeastgenome.org/locus/S000000897/overview)Δ[URA3](http://www.yeastgenome.org/locus/S000000747/overview)[TRP1](http://www.yeastgenome.org/locus/S000002414/overview)[ura3](http://www.yeastgenome.org/locus/S000000747/overview)* query strain for the screen was derived from the sporulation of MCY610. The pinning steps were performed using a ROTOR HDA (Singer Instruments, Somerset, UK) with a 384-density format. The final *[est2](http://www.yeastgenome.org/locus/S000004310/overview)∆natMX [rad51](http://www.yeastgenome.org/locus/S000000897/overview)∆[URA3](http://www.yeastgenome.org/locus/S000000747/overview) xxx∆kanMX* triple mutants (where *xxx∆kanMX* represents a deletion of a gene from the YKO collection) were quadruplicated (*i.e.*, the plate density was increased to 1536), and the resulting four colonies per strain were individually streaked on YPD plates, followed by incubation at 30° for 3 days. The strains were re-streaked 5-6 times until senescence was observed and survivors were formed, or until senescence was observed but no survivors formed.

Telomere Southern blot {#s4}
----------------------

Yeast genomic DNA was isolated using a Wizard Genomic DNA Purification Kit (Promega), digested with *Xho*I, separated on a 1% (w/v) agarose gel, and transferred to a Hybond-N+ membrane (GE Healthcare). The membrane was hybridized to a telomere-specific (5′-CACCACACCCACACACCACACCCACA-3′) digoxygenin-labeled probe.

Measurement of dNTP levels {#s5}
--------------------------

dNTP levels were measured as previously described ([@bib62]).

Data and reagent availability {#s6}
-----------------------------

Strains are available upon request. The authors affirm that all data necessary for confirming the conclusions of the article are present within the article, figures, and tables.

Results and Discussion {#s7}
======================

Screening for novel genes that are important for type II survivor formation {#s8}
---------------------------------------------------------------------------

To identify genes that are important for type II survivor formation, we screened the yeast knockout (YKO) collection for gene deletions that impair the ability of *[est2](http://www.yeastgenome.org/locus/S000004310/overview)∆ [rad51](http://www.yeastgenome.org/locus/S000000897/overview)∆* strains to form type II survivors. We used synthetic genetic array (SGA) methodology ([@bib57]) to create a library of *MAT***a** *[est2](http://www.yeastgenome.org/locus/S000004310/overview)∆ [rad51](http://www.yeastgenome.org/locus/S000000897/overview)∆ xxx∆* mutants, where *xxx∆* is a deletion of a nonessential gene from the YKO collection ([Figure 1](#fig1){ref-type="fig"}). Deletion of *[RAD51](http://www.yeastgenome.org/locus/S000000897/overview)* prevents type I survivor formation ([@bib54]; [@bib10]), allowing us to screen for genes important for type II survivor formation. Each *[est2](http://www.yeastgenome.org/locus/S000004310/overview)∆ [rad51](http://www.yeastgenome.org/locus/S000000897/overview)∆ xxx∆* triple mutant was quadruplicated by replica-pinning, and each replicate was then serially propagated on agar plates to follow senescence and survivor formation (*i.e.*, each *[est2](http://www.yeastgenome.org/locus/S000004310/overview)∆ [rad51](http://www.yeastgenome.org/locus/S000000897/overview)∆ xxx∆* strain was tested four times for its ability to form survivors). 32 triple mutants failed to form survivors in all four replicates, 100 failed to form survivors in three of the four replicates, and 403 failed to form survivors in two of the replicates.

![Screening approach for identifying genes important for type II survivor formation. A *MAT*α *est2∆ rad51∆* query strain was crossed to an ordered array of *MAT***a** viable yeast deletion mutants to generate an array of *est2∆ rad51∆ xxx∆* triple mutants via SGA methodology. The triple mutant strains were then quadruplicated by replica-pinning onto fresh agar plates. The resulting four colonies of each *est2∆ rad51∆ xxx∆* triple mutant was then serially propagated up to six times on sectored YPD plates.](2551f1){#fig1}

All 132 that failed to form survivors in at least three of the four replicates, plus 40 randomly selected that failed to form survivors in two of the four replicates, were further tested by repeating the serial propagation procedure with multiple isolates of single mutants (*[est2](http://www.yeastgenome.org/locus/S000004310/overview)Δ*), double mutants (*[est2](http://www.yeastgenome.org/locus/S000004310/overview)Δ [rad51](http://www.yeastgenome.org/locus/S000000897/overview)Δ*, *[est2](http://www.yeastgenome.org/locus/S000004310/overview)Δ xxxΔ*, *[rad51](http://www.yeastgenome.org/locus/S000000897/overview)Δ xxxΔ*) and triple mutants (*[est2](http://www.yeastgenome.org/locus/S000004310/overview)Δ [rad51](http://www.yeastgenome.org/locus/S000000897/overview)Δ xxxΔ*) obtained by tetrad dissection of sporulated diploids. This allowed us to compare the phenotypic growth between the selected mutants (*e.g.*, to ensure that loss of viability upon serial propagation was not the result of a synthetic genetic interaction between *[rad51](http://www.yeastgenome.org/locus/S000000897/overview)∆* and *xxx∆*) and to validate the hits. In this second test, 26 triple mutants failed to form survivors in \>50% of the multiple isolates. Only one mutant of these 26 was from the 40 that failed to form survivors in two of four replicates in the original screen, so we did not test any additional genes from this group. Importantly, the 26 included strains with a deletion of *[RAD52](http://www.yeastgenome.org/locus/S000004494/overview)*, *[RAD50](http://www.yeastgenome.org/locus/S000005194/overview)*, *[RAD59](http://www.yeastgenome.org/locus/S000002217/overview)*, *[SGS1](http://www.yeastgenome.org/locus/S000004802/overview)*, *[CLB2](http://www.yeastgenome.org/locus/S000006323/overview)*, or *[NMD2](http://www.yeastgenome.org/locus/S000001119/overview)*, which are all known to be required for type II survivor formation ([@bib39]; [@bib54]; [@bib10]; [@bib29]; [@bib34]; [@bib20]; [@bib27]), as well as *[RMI1](http://www.yeastgenome.org/locus/S000005945/overview)* and *[YLR235C](http://www.yeastgenome.org/locus/S000004225/overview)* (which overlaps the *[TOP3](http://www.yeastgenome.org/locus/S000004224/overview)* open reading frame so that deletion of *[YLR235C](http://www.yeastgenome.org/locus/S000004225/overview)* likely results in a *[top3](http://www.yeastgenome.org/locus/S000004224/overview)* hypomorph). Like [Sgs1](http://www.yeastgenome.org/locus/S000004802/overview), [Top3](http://www.yeastgenome.org/locus/S000004224/overview) is also required for type II survivor formation ([@bib59]). [Sgs1](http://www.yeastgenome.org/locus/S000004802/overview), [Top3](http://www.yeastgenome.org/locus/S000004224/overview), and [Rmi1](http://www.yeastgenome.org/locus/S000005945/overview) form an evolutionarily conserved complex ([@bib9]; [@bib45]), so not surprisingly, we find that [Rmi1](http://www.yeastgenome.org/locus/S000005945/overview) is also important for type II survivor formation.

To further validate that these genes are important for type II survivor formation, we knocked out each gene in an *[est2](http://www.yeastgenome.org/locus/S000004310/overview)∆/[EST2](http://www.yeastgenome.org/locus/S000004310/overview)[rad51](http://www.yeastgenome.org/locus/S000000897/overview)∆/[RAD51](http://www.yeastgenome.org/locus/S000000897/overview)* diploid strain of a different genetic background (W303). Once again, we generated haploid meiotic progeny from these diploid strains and serially propagated multiple isolates of each genotype on agar plates to monitor senescence and survivor formation. Overall, 23 genes were identified that are important in type II survivor formation, and of those, 17 genes were not previously reported to be involved in survivor formation ([Table 2](#t2){ref-type="table"}).

###### Genes identified that are important for type II survivor formation

  Gene                                        Fraction of *est2∆ rad51∆ xxx∆* that are able to form survivors   Reference    
  ------------------------------------------- ----------------------------------------------------------------- ------------ --------------------
  *CCR4*[*^b^*](#t2n2){ref-type="table-fn"}                                                                     0/10 (0%)    
  *CDC55*                                     0/12 (0%)                                                         2/9 (22%)    
  *CHK1*                                      5/14 (36%)                                                        2/10 (20%)   
  *CLB2*                                      2/14 (14%)                                                                     [@bib20]
  *DOA4*                                      5/14 (36%)                                                        3/10 (30%)   
  *DUN1*                                      2/12 (17%)                                                        1/25 (4%)    
  *LSM1*                                      5/14 (36%)                                                        0/7 (0%)     
  *MOT2*                                      0/10 (0%)                                                         1/4 (25%)    
  *NMD2*                                      0/12 (0%)                                                                      [@bib27]
  *PPH3*                                      2/12 (17%)                                                        2/10 (20%)   
  *RAD50*                                     2/10 (20%)                                                                     [@bib10]
  *RAD52*                                     0/11 (0%)                                                                      [@bib39]
  *RAD59*                                     4/11 (36%)                                                                     [@bib10]
  *RGI1*                                      0/4 (0%)                                                          2/10 (20%)   
  *RMI1*                                      1/7 (14%)                                                         0/10 (0%)    
  *RPL8B*                                     1/8 (13%)                                                         2/10 (20%)   
  *RPN4*                                      1/9 (11%)                                                         3/10 (30%)   
  *RRM3*                                      4/12 (33%)                                                        3/10 (30%)   
  *SGS1*                                      0/11 (0%)                                                                      [@bib29]; [@bib34]
  *SPT20*                                     0/5 (0%)                                                          0/10 (0%)    
  *VMA22*                                     1/10 (10%)                                                        3/10 (30%)   
  *YLR235C*                                   1/16 (6%)                                                         0/10 (0%)    
  *YLR358C*                                   1/5 (20%)                                                         4/9 (44%)    

These *est2∆ rad51∆ xxx∆* triple mutants were obtained either from the original screen, where four isolates were generated using SGA methodology, or by tetrad dissection of sporulated diploids.

*CCR4* was not identified in the original screen, but was tested in the W303 background due to its functional connection with *MOT2*.

Genes involved in the regulation of dNTP pools are important for type II survivor formation {#s9}
-------------------------------------------------------------------------------------------

We noticed that two of the identified genes, *[DUN1](http://www.yeastgenome.org/locus/S000002259/overview)* and *[MOT2](http://www.yeastgenome.org/locus/S000000870/overview)*, are involved in the regulation of dNTP levels. [Dun1](http://www.yeastgenome.org/locus/S000002259/overview) is a DNA damage checkpoint kinase that phosphorylates and inhibits [Sml1](http://www.yeastgenome.org/locus/S000004523/overview), [Crt1](http://www.yeastgenome.org/locus/S000003746/overview), and [Dif1](http://www.yeastgenome.org/locus/S000004429/overview), three negative regulators of ribonucleotide reductase (RNR) ([@bib68]; [@bib28]; [@bib36]). The RNR complex catalyzes the rate limiting step in dNTP synthesis ([@bib26]). [Mot2](http://www.yeastgenome.org/locus/S000000870/overview) (also known as [Not4](http://www.yeastgenome.org/locus/S000000870/overview)) is part of the Ccr4-Not complex, a key regulator of eukaryotic gene expression that is required for transcriptional induction of *RNR* genes in response to DNA damage or replication stress ([@bib44]). [Ccr4](http://www.yeastgenome.org/locus/S000000019/overview) and [Dun1](http://www.yeastgenome.org/locus/S000002259/overview) cooperate to regulate the Crt1-dependent inhibition of the *RNR* genes in response to DNA replication stress ([@bib65]). Although *[CCR4](http://www.yeastgenome.org/locus/S000000019/overview)* was not identified in our screen, we found that *[est2](http://www.yeastgenome.org/locus/S000004310/overview)∆ [rad51](http://www.yeastgenome.org/locus/S000000897/overview)∆ [ccr4](http://www.yeastgenome.org/locus/S000000019/overview)∆* triple mutants were unable to form survivors ([Table 2](#t2){ref-type="table"}).

The finding that both [Dun1](http://www.yeastgenome.org/locus/S000002259/overview) and the Ccr4-Not complex are important for generating type II survivors suggests that the ability to upregulate intracellular dNTP levels is important for the formation of type II survivors. If so, the compromised ability of cells lacking [Dun1](http://www.yeastgenome.org/locus/S000002259/overview) or the Ccr4-Not complex to form type II survivors should be suppressed by increasing dNTP levels. To test this hypothesis, we examined whether a deletion of *[SML1](http://www.yeastgenome.org/locus/S000004523/overview)* could suppress the defect in survivor formation of *[est2](http://www.yeastgenome.org/locus/S000004310/overview)∆ [rad51](http://www.yeastgenome.org/locus/S000000897/overview)∆ [dun1](http://www.yeastgenome.org/locus/S000002259/overview)∆* cells. [Sml1](http://www.yeastgenome.org/locus/S000004523/overview) inhibits RNR by binding to [Rnr1](http://www.yeastgenome.org/locus/S000000872/overview), the large subunit of RNR ([@bib67]; [@bib8]). Cells lacking [Dun1](http://www.yeastgenome.org/locus/S000002259/overview) have a twofold decrease in dNTP levels, but *[sml1](http://www.yeastgenome.org/locus/S000004523/overview)∆* and *[dun1](http://www.yeastgenome.org/locus/S000002259/overview)∆ [sml1](http://www.yeastgenome.org/locus/S000004523/overview)∆* mutants both have a 2.5-fold increase in dNTP levels ([@bib18]; [@bib67]; [@bib22]). An *[est2](http://www.yeastgenome.org/locus/S000004310/overview)∆/[EST2](http://www.yeastgenome.org/locus/S000004310/overview)[rad51](http://www.yeastgenome.org/locus/S000000897/overview)∆/[RAD51](http://www.yeastgenome.org/locus/S000000897/overview)[dun1](http://www.yeastgenome.org/locus/S000002259/overview)∆/[DUN1](http://www.yeastgenome.org/locus/S000002259/overview)[sml1](http://www.yeastgenome.org/locus/S000004523/overview)∆/[SML1](http://www.yeastgenome.org/locus/S000004523/overview)* diploid was sporulated to generate haploid meiotic progeny, which were serially propagated in liquid medium to monitor senescence and survivor formation. We find that deletion of *[SML1](http://www.yeastgenome.org/locus/S000004523/overview)* largely suppresses the *[dun1](http://www.yeastgenome.org/locus/S000002259/overview)∆* type II survivor formation defect ([Figure 2](#fig2){ref-type="fig"}), suggesting that decreased dNTP levels hinder the formation of type II survivors.

![Deletion of *SML1* suppresses the type II survivor formation defect of a *est2∆ rad51∆ dun1∆* strain. (A) Senescence and survivor formation were monitored in liquid culture by serial passaging of individual isolates of *est2∆ rad51∆ dun1∆* (n = 19, red lines) and *est2∆ rad51∆ dun1∆ sml1∆* (n = 20, blue lines), derived from the sporulation of YPM12. (B) Percentage of *est2∆ rad51∆ dun∆* and *est2∆ rad51∆ dun1∆ sml1∆* cultures from panel A that were able to form survivors. Error bars represent exact binomial 95% confidence intervals; p-value was determined using Fisher's exact test.](2551f2){#fig2}

dNTP pools are upregulated in telomerase-null pre-senescent cells and in type II survivors {#s10}
------------------------------------------------------------------------------------------

To confirm our hypothesis that dNTP levels are important for type II survivor formation, we measured dNTP pools in pre-senescent cells (approximately 35 generations after the loss of telomerase) and in type II survivors ([Figure 3A](#fig3){ref-type="fig"}). Survivor type was determined by a telomere Southern blot ([Figure 3B](#fig3){ref-type="fig"}). We find that dNTP levels are increased in pre-senescent *[est2](http://www.yeastgenome.org/locus/S000004310/overview)∆* cells and remain elevated in type II survivors. Deletion of *[DUN1](http://www.yeastgenome.org/locus/S000002259/overview)* abolishes this increase, a phenotype that is suppressed by an additional deletion of *[SML1](http://www.yeastgenome.org/locus/S000004523/overview)*. These observations suggest that telomere shortening in telomerase-negative cells triggers an increase in dNTP levels that facilitates the generation of type II survivors. Interestingly, an *[est2](http://www.yeastgenome.org/locus/S000004310/overview)∆ [dun1](http://www.yeastgenome.org/locus/S000002259/overview)∆* mutant can still form type II survivors, albeit at a reduced efficiency. This indicates that while an increase in dNTP levels promotes the initial formation of type II survivors, it is not needed for maintenance of the survivors.

![dNTP levels are upregulated in *est2∆* pre-senescent cells and type II survivors. (A) Strains of the indicated genotypes were assayed for dNTP levels. Data are represented as mean ± SE (B) Representative telomere Southern blot of survivors generated by serial propagation in liquid culture of haploid meiotic progeny derived from the sporulation of MCY775. Type I survivors exhibit short telomeres and strong hybridization at 5.2 kb and 6.7 kb due to amplification of the tandemly repeated Y′ short and Y′ long elements, respectively. The telomeres of type II survivors are extended and very heterogeneous in size. The black arrow indicates a 1.8 kb DNA fragment, generated from the BsmAI-digestion of plasmid pYt103 ([@bib48]). This fragment contains telomeric sequences and was ran with each sample as a control.](2551f3){#fig3}

The elevation in dNTP levels occurs relatively early after telomerase inactivation (ETI; within ∼35 population doublings after the generation of *[est2](http://www.yeastgenome.org/locus/S000004310/overview)∆* haploid meiotic progeny), well before a majority of cells become senescent. Consistent with this observation, the DNA damage response and expression of *[RNR3](http://www.yeastgenome.org/locus/S000001328/overview)* is induced in ETI cells ([@bib30]; [@bib66]). In addition, a recent study has shown that ETI cells experience replication stress, resulting in a dependence on the DNA damage response for viability that is alleviated by elevating dNTP pools via a deletion of *[SML1](http://www.yeastgenome.org/locus/S000004523/overview)* ([@bib32]). Taken together, these findings indicate that replication stress occurs in the absence of telomerase, leading to an upregulation of dNTP levels that promotes the formation of type II survivors. Interestingly, we find that dNTP levels stay elevated in type II survivors ([Figure 3](#fig3){ref-type="fig"}), despite these cells looking similar to telomerase-positive wild-type cells in terms of growth rate as well as telomere movement and localization ([@bib55]; [@bib53]). This observation may be due to the fact that dNTP levels are elevated during BIR ([@bib14]), which is required both to prevent accelerated senescence in pre-senescent cells and for telomere elongation in survivors ([@bib17]; [@bib40]).

In summary, this work has identified novel genes important for the formation of type II survivors. We show that dNTP levels increase early after the loss of telomerase, promoting the formation of type II survivors. However, the increased dNTP levels are not required for the maintenance of type II survivors. Given the similarities between type II survivors and human ALT cancer cells, these findings may help us design more effective strategies to combat cancers that use ALT to maintain telomeres.
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